Articles tagged "Induction therapy"

2019 American Transplant Congress
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika
Department of Urology, Ehime University, Toon, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are known to increase the risk of antibody-mediated rejection (ABMR) and graft failure. However, effective methods…
2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
J. Lei¹, H. Deng¹, K. Lee¹, C. Peters¹, G. Rickert¹, R. Ivy¹, M. Coronel², E. Yolcu³, H. Shirwan⁴, A. García⁵, J. Markmann¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Surgery, Georgia Institute of Technology, Atlanta, GA, ³Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, ⁴Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, ⁵School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…
2019 American Transplant Congress
Safety and Efficacy of Alemtuzumab Compared to Rabbit Anti-Thymocyte Globulin as Induction for Secondary Transplant after a Primary Transplant with Alemtuzumab Induction
J. L. Fose¹, M. R. Jorgenson¹, G. E. Leverson², R. R. Redfield²
¹Pharmacy, UW Health, Madison, WI, ²University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI
*Purpose: Alemtuzumab and rabbit anti-thymocyte globulin (rATG) are commonly used lymphocyte depleting induction agents. Traditional thinking suggests that re-transplantation is associated with higher rejection risk,…
2019 American Transplant Congress
Panel Reactive Antibody Stratification as a Guide to Induction Selection in Deceased-Donor Kidney Transplantation: Impact of Clinical Practice on Outcomes
H. Ibrahim¹, J. Gregg¹, K. Alquadan¹, U. Akanit², K. L. Womer¹, A. H. Santos¹
¹Medicine, University of Florida, Gainesville, FL, ²Ubon Ratchathani University, Ubonratchathani, Thailand
*Purpose: We aimed to determine the outcomes associated with anti-thymocyte globulin (ATG), alemtuzumab (ALM) or interleukin-2 receptor antagonist (IL2-RA) induction in adult deceased-donor (DD) kidney…
2019 American Transplant Congress
Simultaneous Pancreas and Kidney Transplant Outcomes after Induction Therapy with Thymoglobulin Compared with Alemtuzumab
B. Masters¹, F. Bartlett², C. Drachenberg³, S. Bartlett³, R. Barth³, J. Scalea³, A. Haririan³
¹University of Maryland Medical Center, Baltimore, MD, ²Barnes-Jewish Hospital, St. Louis, MO, ³University of Maryland, School of Medicine, Baltimore, MD
*Purpose: The purpose of this study is to compare the outcomes of simultaneous pancreas and kidney transplant (SPK) recipients after two T-cell depleting induction agents:…
2019 American Transplant Congress
Alemtuzumab Induction in Living Donor Renal Transplantation
O. Witkowsky, H. Winters, K. Washburn, G. Bumgardner, A. Rajab, A. El-Hinnawi, T. Pesavento
The Ohio State University Wexner Medical center, Columbus, OH
*Purpose: About 15% of kidney transplant (KT) recipients receive alemtuzumab (ALM) for induction. The aim of this study was to review outcomes in living donor…
2019 American Transplant Congress
Evaluation of Rabbit Antithymocyte Globulin (rATG) Dosing and Incidence of Opportunistic Viral Infections in Kidney Transplant Recipients Using Tacrolimus (TAC), Mycophenolate (MPA) and Steroid Free Maintenance Immunosuppression
L. Von Stein, A. Leino, R. Amer, T. Pesavento, H. Winters
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: There is limited literature evaluating rATG dosing and incidence of infection with TAC/MPA and early steroid withdrawal. This study evaluates rATG dosing and overall…
2019 American Transplant Congress
Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant
A. Gil¹, M. Co², M. Calvo-Calle¹, J. Cruz¹, L. Stern¹, L. Gibson²
¹Pathology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA
*Purpose: Human herpesvirus (HHV)-6 reactivation after solid organ or hematopoietic stem cell transplant has been associated with complications such as graft rejection and all-cause mortality.…
2019 American Transplant Congress
Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Lung Transplant in the United States
S. Riad¹, U. Goswami², S. Jackson³, M. Hertz²
¹Medicine, University of Minnesota, Eden Prairie, MN, ²Medicine, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, Fairview Health Services, Minneapolis, MN
*Purpose: Induction regimens for kidney transplant alone (KT) in lung recipients vary widely among transplant centers. We sought to examine the impact of kidney induction…
2019 American Transplant Congress
Effect of Induction Therapy on Absolute CD4 Count and CD4 Percentage in HIV Positive Kidney Transplant Recipients
S. A. Kuten¹, I. E. Dunne¹, A. E. Cantwell¹, M. J. Hobeika², S. G. Yi², W. Musick¹, R. J. Knight², A. O. Gaber²
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: Anti-thymocyte globulin (ATG) induction causes profound and long-lasting lymphocyte depletion, with CD4+ reconstitution lagging behind other subsets. While absolute CD4 count is the preferred…

« Previous Page
1
…
8
9
10
11
12
…
31
Next Page »